휴비츠
Financials
Valuation Metrics
휴비츠's Market Cap is ₩728B. At end of 2025 it was ₩996B. Ranked #1507 of 2,421 in KR market (top 62%), #879 of 1,640 on KOSDAQ (top 54%), #56 of 96 in Health Care Equipment & Services (top 58%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 72.77B KRW | KR#1,507/2,421 Sec#56/96 |
| Revenue | 121.23B KRW | KR#1,308/2,421 Sec#25/96 |
| Net Income | -1.40B KRW | KR—/2,421 Sec—/96 |
| Total Assets | 230.69B KRW | KR#1,212/2,421 Sec#31/96 |
| Net Assets | 114.86B KRW | KR#1,316/2,421 Sec#40/96 |
| Employees | 271 | KR#870/2,421 Sec#26/96 |
| Value | ||
| P/B | 0.63x | KR#1,030/2,421 Sec#19/96 |
| P/S | 0.60x | KR#1,038/2,421 Sec#14/96 |
| EV/EBITDA | 28.29x | KR#1,170/2,421 Sec#38/96 |
| FCF Yield | 7.58% | KR#707/2,421 Sec#17/96 |
| Profitability | ||
| ROE | -1.22% | KR#1,641/2,421 Sec#54/96 |
| ROA | -0.61% | KR#1,629/2,421 Sec#54/96 |
| Op. Margin | 4.27% | KR#1,059/2,421 Sec#41/96 |
| Revenue Growth | 1.88% | KR#1,397/2,421 Sec#70/96 |
| Earnings Growth | -227.57% | KR#1,249/2,421 Sec#46/96 |
| Financial Health | ||
| Debt Ratio | 100.84% | KR#1,563/2,421 Sec#78/96 |
| Total Debt | 77.86B KRW | KR#818/2,421 Sec#16/96 |
| FCF | 5.51B KRW | KR#879/2,421 Sec#24/96 |
| Cash | 4.26B KRW | KR#2,064/2,421 Sec#78/96 |
| Current Ratio | 1.10x | KR#1,608/2,421 Sec#77/96 |
| Net Debt/EBITDA | 14.22x | KR#1,316/2,421 Sec#43/96 |
| Dividend | ||
| Div. Yield | 3.75% | KR#468/2,421 Sec#4/96 |
| Div. Growth | 25.00% | KR#391/2,421 Sec#16/96 |
| Performance | ||
| 1Y Return | -29.13% | KR#1,532/2,421 Sec#38/96 |
| 1M Return | -0.30% | KR#1,273/2,421 Sec#38/96 |
| From 52W High | -33.70% | KR#662/2,421 Sec#19/96 |
| 1Y MDD | -34.79% | KR#398/2,421 Sec#9/96 |
| Trading | ||
| Volume | 14,941 shares | KR#1,737/2,421 Sec#68/96 |
| Trading Value | 99.6M KRW | KR#1,559/2,421 Sec#63/96 |
| Foreign Own. | 3.07% | KR#1,269/2,421 Sec#44/96 |
| Per Share | ||
| EPS | -129 KRW | KR—/2,421 Sec—/96 |
| BPS | 10,559 KRW | KR#953/2,421 Sec#19/96 |
Company Info
Huvitz, established in 1999 and listed on the KOSDAQ market in 2003, plans to expand its implant business by acquiring shares in Osview in 2025. As a specialized ophthalmic medical device company, Huvitz produces South Korea's first optical coherence tomography diagnostic devices and auto refractometers, expanding its business across all optometric fields. The company invests over 10% of its annual revenue in research and development, with R&D personnel comprising 33% of its workforce, growing into a top-tier company in the ophthalmic diagnostic field. Huvitz is headquartered in Anyang-si, Gyeonggi-do.